Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Feb 26, 2026
- Pharmaceuticals
- R&D
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-3 Trial for Type 2 Diabetes)
TOKYO, February 26, 2026 -- Chugai Pharmaceutical Co., Ltd. (hereafter “Chugai”, TOKYO: 4519) announced that Eli Lilly and Company (hereafter “Eli Lilly”, NYSE: LLY) issued a news release on February 26, 2026 (local time) regarding positive full results from the Phase 3 ACHIEVE-3 trial of orforglipron. Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights.
For the full text of Eli Lilly's news release, please refer to the Latest News via the following link:
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
https://investor.lilly.com/
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kozai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp